ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback